Botox Sweating

Hyperhidrosis, or excessive sweating, is a condition that affects millions of people around the world. Uncontrolled sweating can occur in various parts of the body including the face, hands, feet or underarms. Although high temperature or stress can increase perspiration, they don’t cause hyperhidrosis.

Instead, hyperhidrosis may be an inherited trait that stops the body from properly regulating its temperature. Or it may be a symptom of other conditions including anxiety disorders, thyroid malfunction, nerve damage, and menopause. In can also occur as a side effect of medication.

Until now, excessive sweating has been difficult to control. Finally, there is a long lasting treatment for hyperhidrosis that really works.

Botox® for hyperhidrosis

Unlike topical treatments, Botox® targets sweating as its source. With a few tiny injections given by Dr. Pancholi, Botox® enters the specific glands in the underarms responsible for excessive sweating. There, it blocks the release of a chemical that signals the perspiration. This simple, safe procedure takes about 10 minutes.

Patients treated with Botox® notice a remarkable improvement in hyperhidrosis symptoms. In clinical studies, 95% of patients with hyperhidrosis that was severe enough to interfere with their daily lives experienced the benefits of Botox® after just 1 week, with sweating reduced by an average of 83%.

How long does the treatment last?

After the first treatment, the effects of Botox® lasts an average of about 7.5 months. And for nearly 40% of patients, Botox®reduced sweating for more than 1 year. The amount of time Botox® remains effective may vary. When your symptoms begin to return, ask your doctor if it’s time for your next Botox® treatment.

What are the risks involved?

Botox® has been used successfully to treat a range of medical conditions for more than 10 years. Side effects, if they occur, are temporary. The most common side effects with Botox® for axillary hyperhidrosis were a perceived increase in sweating in areas other then the underarms (4.5% of patients), pain at the injection site (1.7%), pain (1.4%), or hot flashes (1%).